Latest Breaking News On - Sage therapeutics - Page 7 : comparemela.com

Citigroup Begins Coverage on Sage Therapeutics (NASDAQ:SAGE)

Citigroup initiated coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage issued a sell rating and a $8.00 price target on the biopharmaceutical company’s stock. SAGE has been the subject of several other reports. The Goldman Sachs Group decreased their price […]

Morgan stanleyProshare advisorsVirtu financialLazard asset managementChina universal asset management coGoldman sachs groupSage therapeutics incFirst advisors incJpmorgan chase coSage therapeuticsFree reportTherapeutics trading downGet free reportAsset managementUniversal asset managementFirst advisors

Sage Therapeutics (NASDAQ:SAGE) Raised to Hold at Baird R W

Baird R W upgraded shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. A number of other analysts have also weighed in on the company. Wedbush reaffirmed a neutral rating and set a $24.00 price objective on shares of Sage Therapeutics […]

United statesGoldman sachs groupFirst advisors incCanaccord genuity groupLazard asset managementVirtu financialQuest partnersSage therapeutics company profileSage therapeutics incChina universal asset management coMorgan stanleySage therapeuticsFree reportGenuity groupTherapeutics stock downGet free report

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc

/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such.

New yorkUnited statesTel avivCity ofUnited kingdomFrance generalDanielle peytonLos angelesAbrahaml pomerantzSage therapeutics incPrnewswire pomerantzSage therapeutics

How a nonprofit group & new postpartum depression pill seek to help those fighting a silent battle

The FDA approved the first pill meant to help parents treat their postpartum depression, but it comes at the cost of $15,900 for a 14-day treatment cycle, but those needing help can turn to a nonprofit organization dedicated to serving the needs of pregnant and new parents.

University of arizonaUnited statesUnited kingdomCarolyn larsenSaira kaliaKaleigh lewisArizona internationalPostpartum support international arizonaUniversity of arizona college medicineCambridge universityDrug administrationPostpartum support internationalClinical neuroscienceSage therapeuticsArizona collegeArizona perinatal psychiatry access line

Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc - SAGE

Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc - SAGE
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesFrance generalCity ofUnited kingdomTel avivLos angelesAbrahaml pomerantzDanielle peytonSage therapeutics incPrnewswire pomerantzSage therapeutics